Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.60 |
| ▸ | HPGD | P15428 | 16/20 | 0.48 |
| ▸ | MEN1 | O00255 | 4/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.48 |
| ▸ | RXFP1 | Q9HBX9 | 4/20 | 0.48 |
| ▸ | USP2 | O75604 | 2/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | CASP1 | P29466 | 1/20 | 0.47 |
| ▸ | CASP7 | P55210 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4895355 | 0.99 | MAPT (0.61) | MAPTKDM4EALDH1A1L3MBTL1MAPK1 | |
| SCHEMBL4901029 | 0.89 | HPGD (0.60) | MAPTKDM4EALDH1A1L3MBTL1MAPK1 | |
| SCHEMBL4900837 | 0.88 | KDM4E (0.61) | MAPTKDM4EALDH1A1L3MBTL1MAPK1 | |
| SCHEMBL4901399 | 0.88 | KAT8 (0.52) | MAPTKDM4EALDH1A1L3MBTL1MAPK1 | |
| SCHEMBL4899933 | 0.79 | MAPT (0.63) | MAPTKDM4EALDH1A1L3MBTL1MAPK1 | |
| SCHEMBL4894356 | 0.78 | HPGD (0.58) | MAPTKDM4EALDH1A1L3MBTL1MAPK1 | |
| SCHEMBL4902489 | 0.78 | KDM4E (0.59) | MAPTKDM4EALDH1A1L3MBTL1MAPK1 | |
| SCHEMBL4899997 | 0.77 | MAPT (0.50) | MAPTKDM4EALDH1A1L3MBTL1MAPK1 | |
| SCHEMBL430490 | 0.74 | LIMK1 (0.67) | MAPTKDM4EALDH1A1L3MBTL1MAPK1 | |
| SCHEMBL4900157 | 0.73 | HPGD (0.62) | MAPTKDM4EHPGDKMT2ACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080008720-A1 | Substituted Tricyclic Heterocycles and their Uses | CYWIN CHARLES L | 2008-01-10 | — | — | US | disclosed |
| US-7291733-B2 | Substituted tricyclic heterocycles and their uses | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2007-11-06 | — | — | US | disclosed |
| US-20050101601-A1 | Substituted tricyclic heterocycles and their uses | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050101601-A1 | Substituted tricyclic heterocycles and their uses | LTC4S, NQO1, CBR3 | MAPT 4573/4885KDM4E 3715/4885ALDH1A1 270/4885 |
| US-20080008720-A1 | Substituted Tricyclic Heterocycles and their Uses | LTC4S, NQO1, CBR3 | MAPT 4573/4885KDM4E 3715/4885ALDH1A1 270/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.